ARQ-151 vehicle cream

DRUG2 trials

Sponsors

Arcutis Biotherapeutics, Inc.

Conditions

Chronic Plaque PsoriasisPsoriasis

Phase 1

Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis

CompletedNCT03392168

Arcutis Biotherapeutics, Inc.Psoriasis

Start: 2017-12-11End: 2018-05-02Updated: 2022-08-04

Phase 3

Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

CompletedNCT04211389

Arcutis Biotherapeutics, Inc.Chronic Plaque Psoriasis

Start: 2019-12-17End: 2020-11-23Updated: 2022-12-07

Related Papers

Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials.

2025-10-24

504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis

British Journal of Dermatology2024-02-01

Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Individual Patient PASI and PASI-HD Responses: Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials

SKIN The Journal of Cutaneous Medicine2024-01-19

Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Individual Patient Response from the Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials

SKIN The Journal of Cutaneous Medicine2024-01-16

Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis

SKIN The Journal of Cutaneous Medicine2024-01-16

Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies.

2022-11-2417 citations

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis

JAMA2022-09-20103 citations

Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study

Journal of Drugs in Dermatology2020-07-0125 citations